Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 113 articles:
HTML format
Text format



Single Articles


    June 2018
  1. PRINTZ C
    Combined therapies improve survival in aggressive prostate cancer.
    Cancer. 2018;124:2470.
    PubMed     Text format    


    May 2018
  2. NEGOITA S, Feuer EJ, Mariotto A, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
    Cancer. 2018 May 22. doi: 10.1002/cncr.31549.
    PubMed     Text format     Abstract available


  3. THOMPSON IM JR
    The pendulum swings back: Screening for prostate cancer in 2018.
    Cancer. 2018 May 22. doi: 10.1002/cncr.31555.
    PubMed     Text format    


  4. KEARNS JT, Holt SK, Wright JL, Lin DW, et al
    PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Cancer. 2018 May 21. doi: 10.1002/cncr.31337.
    PubMed     Text format     Abstract available


  5. FILSON CP
    Moving toward a more rational, evidence-based approach to PSA screening, diagnosis, and treatment of prostate cancer.
    Cancer. 2018 May 21. doi: 10.1002/cncr.31332.
    PubMed     Text format    


  6. BRYANT AK, D'Amico AV, Nguyen PL, Einck JP, et al
    Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
    Cancer. 2018 May 4. doi: 10.1002/cncr.31400.
    PubMed     Text format     Abstract available


  7. BRAWLEY OW
    Prostate cancer screening: And the pendulum swings.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31380.
    PubMed     Text format    


  8. HELGSTRAND JT, Roder MA, Klemann N, Toft BG, et al
    Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31384.
    PubMed     Text format     Abstract available


    April 2018
  9. ZHEN JT, Syed J, Nguyen KA, Leapman MS, et al
    Genetic testing for hereditary prostate cancer: Current status and limitations.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31316.
    PubMed     Text format     Abstract available


  10. REEVE BB, Tan X, Chen RC, Usinger DS, et al
    Symptom and function profiles of men with localized prostate cancer.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31401.
    PubMed     Text format     Abstract available


    March 2018
  11. GOLAN R, Bernstein AN, Gu X, Dinerman BA, et al
    Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31297.
    PubMed     Text format     Abstract available


  12. DALL'ERA MA, Lo MJ, Chen J, Cress R, et al
    Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31285.
    PubMed     Text format     Abstract available


    January 2018
  13. KAUR D, Ulloa-Perez E, Gulati R, Etzioni R, et al
    Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
    Cancer. 2018 Jan 25. doi: 10.1002/cncr.31253.
    PubMed     Text format     Abstract available


  14. MCHUGH DJ, Root JC, Nelson CJ, Morris MJ, et al
    Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31153.
    PubMed     Text format     Abstract available


  15. MCDUFF SGR, Chen MH, Renshaw AA, Loffredo MJ, et al
    Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31217.
    PubMed     Text format     Abstract available


  16. PRINTZ C
    Evolving detection and treatment methods change approaches to prostate cancer: US Preventive Services Task Force draft recommendations now align more closely with others.
    Cancer. 2018;124:11-12.
    PubMed     Text format    


    December 2017
  17. ATKINS KM, Chen MH, Wu J, Renshaw AA, et al
    Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31204.
    PubMed     Text format     Abstract available


  18. SAILER V, Schiffman MH, Kossai M, Cyrta J, et al
    Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31173.
    PubMed     Text format     Abstract available


  19. PAL SK, Patel J, He M, Foulk B, et al
    Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31161.
    PubMed     Text format     Abstract available


  20. STEELE CB, Li J, Huang B, Weir HK, et al
    Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5160-5177.
    PubMed     Text format     Abstract available


  21. DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
    Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31141.
    PubMed     Text format     Abstract available


  22. ALBERTSEN PC
    Prostate cancer screening with prostate-specific antigen: Where are we going?
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31140.
    PubMed     Text format    


  23. MAHAL BA, Chen YW, Sethi RV, Padilla OA, et al
    Travel distance and stereotactic body radiotherapy for localized prostate cancer.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31190.
    PubMed     Text format     Abstract available


  24. ALIBHAI SMH, Breunis H, Timilshina N, Hamidi MS, et al
    Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31171.
    PubMed     Text format     Abstract available


    November 2017
  25. ALBISINNI S, Joniau S, Quackels T, De Coster G, et al
    Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium.
    Cancer. 2017;123:4139-4146.
    PubMed     Text format     Abstract available


  26. FREEDLAND SJ, Vidal AC, Howard LE, Terris MK, et al
    Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
    Cancer. 2017;123:4199-4206.
    PubMed     Text format     Abstract available


    October 2017
  27. MAHAL AR, Mahal BA, Nguyen PL, Yu JB, et al
    Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance.
    Cancer. 2017 Oct 30. doi: 10.1002/cncr.31106.
    PubMed     Text format     Abstract available


  28. GONZALEZ BD, Small BJ, Cases MG, Williams NL, et al
    Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31024.
    PubMed     Text format     Abstract available


  29. BORZA T, Kaufman SR, Yan P, Herrel LA, et al
    Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31081.
    PubMed     Text format     Abstract available


  30. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Text format     Abstract available


  31. CAMPODONICO F, Grillo-Ruggeri F, Grimaldi A, Zanardi S, et al
    Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow-up.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31054.
    PubMed     Text format    


  32. HURWITZ LM, Cullen J
    Reply to Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow-up.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31053.
    PubMed     Text format    


    September 2017
  33. LOPPENBERG B, Friedlander DF, Krasnova A, Tam A, et al
    Variation in the use of active surveillance for low-risk prostate cancer.
    Cancer. 2017 Sep 13. doi: 10.1002/cncr.30983.
    PubMed     Text format     Abstract available


    August 2017
  34. YANG DD, Mahal BA, Muralidhar V, Boldbaatar N, et al
    Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
    Cancer. 2017 Aug 22. doi: 10.1002/cncr.30948.
    PubMed     Text format     Abstract available


  35. HOFFMAN RM, Volk RJ, Wolf AMD
    Making the grade: The newest US Preventive Services Task Force prostate cancer screening recommendation.
    Cancer. 2017 Aug 22. doi: 10.1002/cncr.30941.
    PubMed     Text format    


  36. PRINTZ C
    Active surveillance helps prostate cancer patients keep quality of life, findings show.
    Cancer. 2017;123:2997.
    PubMed     Text format    


  37. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available


  38. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Text format     Abstract available


  39. GORE JL, du Plessis M, Santiago-Jimenez M, Yousefi K, et al
    Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.
    Cancer. 2017;123:2850-2859.
    PubMed     Text format     Abstract available


    July 2017
  40. POLLACK CE, Armstrong KA, Mitra N, Chen X, et al
    A multidimensional view of racial differences in access to prostate cancer care.
    Cancer. 2017 Jul 20. doi: 10.1002/cncr.30894.
    PubMed     Text format     Abstract available


  41. EBOT EM, Gerke T, Labbe DP, Sinnott JA, et al
    Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.
    Cancer. 2017 Jul 12. doi: 10.1002/cncr.30831.
    PubMed     Text format     Abstract available


  42. HURWITZ LM, Cullen J, Kim DJ, Elsamanoudi S, et al
    Longitudinal regret after treatment for low- and intermediate-risk prostate cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30841.
    PubMed     Text format     Abstract available


  43. LEWIS DR, Chen HS, Cockburn MG, Wu XC, et al
    Early estimates of SEER cancer incidence, 2014.
    Cancer. 2017;123:2524-2534.
    PubMed     Text format     Abstract available


    June 2017
  44. SCHULMAN AA, Howard LE, Tay KJ, Tsivian E, et al
    Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30844.
    PubMed     Text format     Abstract available


  45. PILIE PG, Johnson AM, Hanson KL, Dayno ME, et al
    Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Cancer. 2017 Jun 28. doi: 10.1002/cncr.30817.
    PubMed     Text format     Abstract available


  46. POMERANTZ MM, Spisak S, Jia L, Cronin AM, et al
    The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
    Cancer. 2017 Jun 13. doi: 10.1002/cncr.30808.
    PubMed     Text format     Abstract available


  47. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
    The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Cancer. 2017;123:1912-1924.
    PubMed     Text format     Abstract available


    May 2017
  48. FRENDL DM, Olumi AF
    Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30779.
    PubMed     Text format    


  49. LI TT, Shore ND, Mehra M, Todd MB, et al
    Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30784.
    PubMed     Text format     Abstract available


  50. RADHAKRISHNAN A, Grande D, Mitra N, Bekelman J, et al
    Second opinions from urologists for prostate cancer: Who gets them, why, and their link to treatment.
    Cancer. 2017;123:1027-1034.
    PubMed     Text format     Abstract available


  51. VETTERLEIN MW, Loppenberg B, Karabon P, Dalela D, et al
    Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30744.
    PubMed     Text format     Abstract available


    April 2017
  52. WALLNER LP, Jacobsen SJ
    Prostate cancer in black men: Is it time for personalized screening approaches?
    Cancer. 2017 Apr 24. doi: 10.1002/cncr.30685.
    PubMed     Text format    


  53. TSODIKOV A, Gulati R, de Carvalho TM, Heijnsdijk EAM, et al
    Is prostate cancer different in black men? Answers from 3 natural history models.
    Cancer. 2017 Apr 24. doi: 10.1002/cncr.30687.
    PubMed     Text format     Abstract available


  54. LAYNE TM, Weinstein SJ, Graubard BI, Ma X, et al
    Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30634.
    PubMed     Text format     Abstract available


    March 2017
  55. HURWITZ MD, Harris J, Sartor O, Xiao Y, et al
    Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Cancer. 2017 Mar 21. doi: 10.1002/cncr.30620.
    PubMed     Text format     Abstract available


  56. JACOBS BL, Yabes JG, Lopa SH, Heron DE, et al
    The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30574.
    PubMed     Text format     Abstract available



  57. Erratum: Activation of nuclear factor kappaB pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer.
    Cancer. 2017;123:892-893.
    PubMed     Text format    


    February 2017
  58. ADAMO MP, Boten JA, Coyle LM, Cronin KA, et al
    Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
    Cancer. 2017;123:697-703.
    PubMed     Text format     Abstract available


  59. GOKCE MI, Wang X, Frost J, Roberson P, et al
    Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men.
    Cancer. 2017;123:583-591.
    PubMed     Text format     Abstract available


  60. ARMSTRONG AJ, Saad F, Phung, Dmuchowski C, et al
    Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30587.
    PubMed     Text format     Abstract available


  61. PETTERSSON A, Gerke T, Fall K, Pawitan Y, et al
    The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies.
    Cancer. 2017 Feb 2. doi: 10.1002/cncr.30582.
    PubMed     Text format     Abstract available


  62. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    PubMed     Text format     Abstract available


    January 2017
  63. LAI WS, Gordetsky JB, Thomas JV, Nix JW, et al
    Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Cancer. 2017 Jan 31. doi: 10.1002/cncr.30548.
    PubMed     Text format     Abstract available


  64. KIM H, Kalchman I, Santiago-Jimenez M, Lehrer J, et al
    Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.
    Cancer. 2017 Jan 31. doi: 10.1002/cncr.30580.
    PubMed     Text format     Abstract available


  65. WILLIAMS SB, Huo J, Chamie K, Smaldone MC, et al
    Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.
    Cancer. 2017 Jan 18. doi: 10.1002/cncr.30506.
    PubMed     Text format     Abstract available


  66. BERNARD B, Muralidhar V, Chen YH, Sridhar SS, et al
    Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
    Cancer. 2017 Jan 5. doi: 10.1002/cncr.30503.
    PubMed     Text format     Abstract available


  67. PRINTZ C
    Smokeless tobacco product may increase mortality rate in patients with prostate cancer.
    Cancer. 2017;123:190.
    PubMed     Text format    


  68. COLLINS GS, Le Manach Y
    Nomograms need to be presented in full.
    Cancer. 2017;123:177-178.
    PubMed     Text format    


    December 2016
  69. KLAASSEN Z, Howard LE, de Hoedt A, Amling CL, et al
    Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30505.
    PubMed     Text format     Abstract available


  70. DESS RT, Jackson WC, Suy S, Soni PD, et al
    Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
    Cancer. 2016 Dec 21. doi: 10.1002/cncr.30519.
    PubMed     Text format     Abstract available


  71. GULATI R, Albertsen PC
    Insights from the PLCO trial about prostate cancer screening.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30472.
    PubMed     Text format    


  72. PINSKY PF, Prorok PC, Yu K, Kramer BS, et al
    Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30474.
    PubMed     Text format     Abstract available


    November 2016
  73. CHEN RC
    Lymph node-positive prostate cancer-From middle child to the new frontier.
    Cancer. 2016 Nov 8. doi: 10.1002/cncr.30374.
    PubMed     Text format    


  74. JEGADEESH N, Liu Y, Zhang C, Zhong J, et al
    The role of adjuvant radiotherapy in pathologically lymph node positive prostate cancer.
    Cancer. 2016 Nov 8. doi: 10.1002/cncr.30373.
    PubMed     Text format     Abstract available


  75. FRANCINI E, Taplin ME
    Prostate cancer: Developing novel approaches to castration-sensitive disease.
    Cancer. 2016 Nov 1. doi: 10.1002/cncr.30329.
    PubMed     Text format     Abstract available


    September 2016
  76. KEARNS JT, Gore JL
    Prostate cancer screening: Do guidelines matter?
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30331.
    PubMed     Text format    


  77. REKOSKE BT, McNeel DG
    Immunotherapy for prostate cancer: False promises or true hope?
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30250.
    PubMed     Text format     Abstract available


  78. LORIOT Y, Fizazi K, de Bono JS, Forer D, et al
    Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30336.
    PubMed     Text format     Abstract available


  79. HOLMES JA, Bensen JT, Mohler JL, Song L, et al
    Quality of care received and patient-reported regret in prostate cancer: Analysis of a population-based prospective cohort.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30315.
    PubMed     Text format     Abstract available


  80. ALIBHAI SM, Timilshina N, Duff-Canning S, Breunis H, et al
    Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.
    Cancer. 2016 Sep 1. doi: 10.1002/cncr.30320.
    PubMed     Text format     Abstract available


    August 2016
  81. WHITNEY CA, Howard LE, Amling CL, Aronson WJ, et al
    Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
    Cancer. 2016 Aug 9. doi: 10.1002/cncr.30221.
    PubMed     Text format     Abstract available


  82. KOVTUN KA, Chen MH, Braccioforte MH, Moran BJ, et al
    Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
    Cancer. 2016 Aug 4. doi: 10.1002/cncr.30224.
    PubMed     Text format     Abstract available


    July 2016
  83. CARLSSON SV, de Carvalho TM, Roobol MJ, Hugosson J, et al
    Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30192.
    PubMed     Text format     Abstract available


  84. MAHAL BA, Chen YW, Muralidhar V, Mahal AR, et al
    National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?
    Cancer. 2016 Jul 19. doi: 10.1002/cncr.30205.
    PubMed     Text format     Abstract available


  85. TURNER AR, Lane BR, Rogers D, Lipkus I, et al
    Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.
    Cancer. 2016 Jul 19. doi: 10.1002/cncr.30162.
    PubMed     Text format     Abstract available


  86. JACOBS BL, Lopa SH, Yabes JG, Nelson JB, et al
    Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population.
    Cancer. 2016 Jul 5. doi: 10.1002/cncr.30184.
    PubMed     Text format     Abstract available


    June 2016
  87. WANG K, Sheets NC, Basak R, Chen RC, et al
    Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30154.
    PubMed     Text format     Abstract available


  88. KASUYA G, Ishikawa H, Tsuji H, Nomiya T, et al
    Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30050.
    PubMed     Text format     Abstract available


    May 2016
  89. HALPERN JA, Sedrakyan A, Hsu WC, Mao J, et al
    Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
    Cancer. 2016 May 25. doi: 10.1002/cncr.30101.
    PubMed     Text format     Abstract available


  90. MCPARTLIN AJ, Glicksman R, Pintilie M, Tsuji D, et al
    PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.
    Cancer. 2016 May 24. doi: 10.1002/cncr.30093.
    PubMed     Text format     Abstract available


  91. FALCHOOK AD, Basak R, Mohiuddin JJ, Chen RC, et al
    Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Cancer. 2016 May 18. doi: 10.1002/cncr.30049.
    PubMed     Text format     Abstract available


  92. KEANE FK, D'Amico AV
    Androgen deprivation therapy use and risk of death in men treated with high-dose radiation for intermediate-risk prostate cancer.
    Cancer. 2016 May 18. doi: 10.1002/cncr.30048.
    PubMed     Text format    


  93. VERMA V, Mishra MV, Mehta MP
    A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
    Cancer. 2016;122:1483-501.
    PubMed     Text format     Abstract available


  94. BAKER BR, Basak R, Mohiuddin JJ, Chen RC, et al
    Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.
    Cancer. 2016 May 12. doi: 10.1002/cncr.30034.
    PubMed     Text format     Abstract available


  95. PRICE DK, Chau CH, Till C, Goodman PJ, et al
    Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
    Cancer. 2016 May 10. doi: 10.1002/cncr.30071.
    PubMed     Text format     Abstract available


  96. SHUI IM, Wong CJ, Zhao S, Kolb S, et al
    Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30045.
    PubMed     Text format     Abstract available


    March 2016
  97. VIANI GA, Viana BS, Martin JE, Rossi BT, et al
    Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Cancer. 2016 Mar 29. doi: 10.1002/cncr.29983.
    PubMed     Text format     Abstract available


  98. CHOW H, Ghosh PM, deVere White R, Evans CP, et al
    A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
    Cancer. 2016 Mar 28. doi: 10.1002/cncr.29927.
    PubMed     Text format     Abstract available



  99. Erratum: Long-term quality of life among Dutch prostate cancer survivors.
    Cancer. 2016;122:974.
    PubMed     Text format    


  100. PRINTZ C
    Early-stage prostate cancer, PSA screening rates decline.
    Cancer. 2016;122:825.
    PubMed     Text format    


  101. MAHAL BA, Chen YW, Efstathiou JA, Muralidhar V, et al
    National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study.
    Cancer. 2016 Mar 11. doi: 10.1002/cncr.29960.
    PubMed     Text format     Abstract available


  102. MOR V, Joyce NR, Cote DL, Gidwani RA, et al
    The rise of concurrent care for veterans with advanced cancer at the end of life.
    Cancer. 2016;122:782-90.
    PubMed     Text format     Abstract available


  103. WRIGHT BJ, Conlin AK, Allen HL, Tsui J, et al
    What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverage.
    Cancer. 2016;122:791-7.
    PubMed     Text format     Abstract available


    February 2016
  104. DESAUTELS D, Czaykowski P, Nugent Z, Demers AA, et al
    Risk of colorectal cancer after the diagnosis of prostate cancer: A population-based study.
    Cancer. 2016 Feb 25. doi: 10.1002/cncr.29919.
    PubMed     Text format     Abstract available


  105. PRINTZ C
    Racial difference seen in outcomes for older patients with prostate cancer.
    Cancer. 2016;122:501.
    PubMed     Text format    


  106. SANYAL C, Aprikian AG, Cury FL, Chevalier S, et al
    Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
    Cancer. 2016 Feb 1. doi: 10.1002/cncr.29892.
    PubMed     Text format     Abstract available


  107. TEVAARWERK AJ, Lee JW, Terhaar A, Sesto ME, et al
    Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.
    Cancer. 2016;122:438-46.
    PubMed     Text format     Abstract available


    January 2016
  108. FILSON CP, Natarajan S, Margolis DJ, Huang J, et al
    Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
    Cancer. 2016 Jan 7. doi: 10.1002/cncr.29874.
    PubMed     Text format     Abstract available


    December 2015

  109. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P and Freedland SJ. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortalit
    Cancer. 2015;121:4272.
    PubMed     Text format    



  110. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R and Freedland SJ. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study.
    Cancer. 2015;121:4271.
    PubMed     Text format    


    November 2015
  111. NYROP KA, Deal AM, Williams GR, Guerard EJ, et al
    Physical activity communication between oncology providers and patients with early-stage breast, colon, or prostate cancer.
    Cancer. 2015 Nov 13. doi: 10.1002/cncr.29786.
    PubMed     Text format     Abstract available


    September 2015
  112. DREYFUS M, Wion D
    Investigating the relationship between vitamin D and cancer requires dosing the bioavailable nonhydroxylated vitamin D storage in cancer tissues.
    Cancer. 2015;121:3362-3.
    PubMed     Text format    


  113. SHUI IM, Giovannucci E
    Reply to investigating the relationship between vitamin d and cancer requires dosing the bioavailable nonhydroxylated vitamin d storage in cancer tissues.
    Cancer. 2015;121:3363-4.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: